Gamida Cell (NASDAQ:GMDA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Gamida Cell (NASDAQ:GMDA) announced its quarterly earnings data on Thursday. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.12, MarketWatch Earnings reports.

Gamida Cell stock opened at $5.31 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.98 and a current ratio of 4.98. Gamida Cell has a fifty-two week low of $2.60 and a fifty-two week high of $7.70. The stock has a market cap of $107.06 million, a P/E ratio of -2.40 and a beta of 1.97. The firm’s fifty day moving average price is $4.20 and its 200-day moving average price is $4.43.

GMDA has been the subject of several recent research reports. HC Wainwright started coverage on shares of Gamida Cell in a research note on Monday, April 27th. They issued a “buy” rating and a $15.00 target price for the company. Zacks Investment Research upgraded shares of Gamida Cell from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, May 15th. Needham & Company LLC dropped their target price on Gamida Cell from $19.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday. BMO Capital Markets reduced their price target on Gamida Cell from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Oppenheimer boosted their price objective on Gamida Cell from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Seven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $15.33.

About Gamida Cell

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia.

Further Reading: What is the G-20?

Earnings History for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with's FREE daily email newsletter.